共 31 条
- [21] γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiationBlood Cancer Journal, 12Hailin ChenTengteng YuLiang LinLijie XingShih-Feng ChoKenneth WenKimberly AardalenAdwait OkaJoni LamMike DaleyHaihui LuNikhil MunshiKenneth C. AndersonYu-Tzu Tai
- [22] γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiationBLOOD CANCER JOURNAL, 2022, 12 (08)Chen, HailinYu, TengtengLin, LiangXing, LijieCho, Shih-FengWen, KennethAardalen, KimberlyOka, AdwaitLam, JoniDaley, MikeLu, HaihuiMunshi, NikhilAnderson, Kenneth C.Tai, Yu-Tzu
- [23] Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody ApproachANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (08)Tkaczyk, C.Kasturirangan, S.Minola, A.Jones-Nelson, O.Gunter, V.Shi, Y. Y.Rosenthal, K.Aleti, V.Semenova, E.Warrener, P.Tabor, D.Stover, C. K.Corti, D.Rainey, G.Sellman, B. R.
- [24] A NOVEL BISPECIFIC BCA356 TARGETING TUMOUR ANTIGEN CAIX CONJUGATED TO AN ATTENUATED IL12 DEMONSTRATES PRE-CLINICAL EFFICACY WITH POTENTIAL FOR LIMITED SYSTEMIC TOXICITYJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1419 - A1420Nair, PradipGoswamy, ArvindBhatnagar, JayaBoreddy, SrinivasNair, ReshmiKrishn, ShivKuriakose, AnshuPandey, PrashanthKulkarni, HanumantPunnath, KishoreSagar, MilindPrashanthakumara, VThulsi, T. K.Sinha, AbhishekRavindra, D. R.Salazar, Rachel
- [25] BVX001, a Bispecific ADC Targeting CD7-Positive AML with Favorable Toxicity Profile, Exhibits Significant Efficacy in Primary Patient Samples and PDX-ModelsBLOOD, 2024, 144 : 2773 - 2774Vitale, MattiaGriffiths, Hollie B. S.Jones, NyleMistry, MeeraSangster, JackPatterson, ChloeO'Halloran, Samuel E.Blanco-Gomez, AdrianSchon, OliverThorn, Tiffany
- [26] Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trialJOURNAL OF NUCLEAR MEDICINE, 2006, 47 (02) : 247 - 255Kraeber-Bodéré, FRousseau, CBodet-Milin, CFerrer, LFaivre-Chauvet, ACampion, LVuillez, JPDevillers, AChang, CHGoldenberg, DMChatal, JFBarbet, J
- [27] Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumorsDRUG DELIVERY, 2018, 25 (01) : 1066 - 1079Su, Chia-YuChen, MichaelChen, Ling-ChunHo, Yuan-SoonHo, Hsiu-OLin, Shyr-YiChuang, Kuo-HsiangSheu, Ming-Thau
- [28] Translational PK/PD/efficacy modeling and efficacious human dose prediction for a first-in-class MUC1-EGFR (M1231) bispecific antibody drug conjugateCANCER RESEARCH, 2022, 82 (12)Zutshi, AnupNeuteboom, BerendKumar, SeemaSloot, WillemKnuehl, ChristineDotterweich, JuliaMa, JianguoAmendt, ChristianeVenkatakrishnan, KarthikPark, TaeshinPappas, JohnKim, Kyoung-Ae
- [29] Deconstructing SARS-CoV-2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nanobodies targeting the spike RBDJOURNAL OF MEDICAL VIROLOGY, 2023, 95 (06)Tragni, VincenzoMercurio, IvanPaoletti, Diletta PiaOnofrio, AngeloLaera, LunaBeltrame, Lucas CafferatiSgobba, Maria NoemiGuerra, LorenzoVolpicella, MariateresaDe Grassi, AnnaElia, GabriellaPierri, Ciro Leonardo
- [30] FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, is designed for optimal CD137 interactions resulting in potent T cell activation without toxicity.CANCER RESEARCH, 2021, 81 (13)Lakins, Matthew A.Munoz-Olaya, JoseVeyssier, ChristelJones, DanielGoodman, EmmaKaka, QuincyOfoedu, JenniferHughes, RobertGliddon, DanielMorrow, MichelleBrewis, Neil